Letters to the Editor

Brentuximab vedotin with chemotherapy in adolescents and young adults with stage III or IV classical Hodgkin lymphoma in ECHELON-1

Bon Secours Hematology and Oncology, Bon Secours, St. Francis Health System, Greenville, SC
Dana-Farber Cancer Institute, Partners Cancer Care, Boston, MA
Siteman Cancer Center, Washington University School of Medicine, St Louis, MO
Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
British Columbia Cancer Agency, Vancouver, BC
IRCCS University Hospital of Bologna, Institute of Hematology “Seràgnoli,” Bologna, Italy; Department of Specialized Medicine, Diagnostic and Experimental, University of Bologna, Bologna
Oxford University Hospitals NHS Foundation Trust, Oxford
Seagen Inc., Bothell, WA
Seagen Inc., Bothell, WA
Takeda Development Center Americas, Inc. (TDCA), Lexington, MA
Takeda Development Center Americas, Inc. (TDCA), Lexington, MA
Department of Clinical Haematology, Austin Hospital, VIC
Vol. 109 No. 3 (2024): March, 2024 https://doi.org/10.3324/haematol.2023.283303